PL1758852T3 - Podstawione związki cyklopentenu - Google Patents

Podstawione związki cyklopentenu

Info

Publication number
PL1758852T3
PL1758852T3 PL05747867T PL05747867T PL1758852T3 PL 1758852 T3 PL1758852 T3 PL 1758852T3 PL 05747867 T PL05747867 T PL 05747867T PL 05747867 T PL05747867 T PL 05747867T PL 1758852 T3 PL1758852 T3 PL 1758852T3
Authority
PL
Poland
Prior art keywords
substituted cyclopentene
compounds
cyclopentene compounds
substituted
production
Prior art date
Application number
PL05747867T
Other languages
English (en)
Inventor
Oswald Zimmer
Michael Haurand
Klaus Schiene
Clemens Gillen
Johannes Schneider
Gregor Bahrenberg
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL1758852T3 publication Critical patent/PL1758852T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/56—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05747867T 2004-06-09 2005-06-07 Podstawione związki cyklopentenu PL1758852T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004027912A DE102004027912A1 (de) 2004-06-09 2004-06-09 Substituierte Cyclopenten-Verbindungen
US10/993,545 US7109214B2 (en) 2004-06-09 2004-11-19 Substituted cyclopentene compounds
EP05747867A EP1758852B1 (de) 2004-06-09 2005-06-07 Substituierte cyclopenten-verbindungen
PCT/EP2005/006092 WO2005121078A2 (de) 2004-06-09 2005-06-07 Substituierte cyclopenten-verbindungen

Publications (1)

Publication Number Publication Date
PL1758852T3 true PL1758852T3 (pl) 2010-02-26

Family

ID=35449934

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05747867T PL1758852T3 (pl) 2004-06-09 2005-06-07 Podstawione związki cyklopentenu

Country Status (7)

Country Link
US (1) US7109214B2 (pl)
EP (1) EP1758852B1 (pl)
AT (1) ATE441630T1 (pl)
DE (2) DE102004027912A1 (pl)
ES (1) ES2332922T3 (pl)
PL (1) PL1758852T3 (pl)
WO (1) WO2005121078A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
ES2616539T3 (es) * 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) * 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
EP3115062A1 (en) 2008-03-04 2017-01-11 Labrys Biologics Inc. Methods of treating inflammatory pain
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
IN2012DN02521A (pl) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US20220387357A1 (en) * 2021-06-04 2022-12-08 Cytometix, Inc. Method of Dosing a Pain Therapeutic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
CN1143365A (zh) * 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 作为cox-2抑制剂的苯基杂环类化合物
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6222048B1 (en) * 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO1997028121A1 (en) 1996-02-01 1997-08-07 Merck Frosst Canada Inc. Alkylated styrenes as prodrugs to cox-2 inhibitors
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
CA2397076A1 (en) 2000-02-04 2001-08-09 Calyx Therapeutics, Inc. Novel diphenylethylene compounds
CA2492066A1 (en) 2002-06-28 2004-01-08 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

Also Published As

Publication number Publication date
WO2005121078A2 (de) 2005-12-22
EP1758852A2 (de) 2007-03-07
EP1758852B1 (de) 2009-09-02
US20050272955A1 (en) 2005-12-08
US7109214B2 (en) 2006-09-19
DE102004027912A1 (de) 2005-12-29
ATE441630T1 (de) 2009-09-15
ES2332922T3 (es) 2010-02-15
DE502005008057D1 (de) 2009-10-15
WO2005121078A3 (de) 2006-03-23

Similar Documents

Publication Publication Date Title
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
MXPA05009068A (es) Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
SE0401762D0 (sv) Novel compounds
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
PL1758852T3 (pl) Podstawione związki cyklopentenu
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
TW200639156A (en) New compounds
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
TW200635917A (en) Novel compounds
TW200745122A (en) New compounds I
MXPA05012679A (es) Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
TW200605888A (en) Novel compounds
TW200635916A (en) Compounds
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
SI1745010T1 (sl) Substituirani cikloheksil-1,4-diaminski derivati
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200609222A (en) Diazole derivatives
TW200722418A (en) Novel compounds